LAUSR

Membranopathies are a group of inherited blood disorders where the diagnosis could form a challenge due to phenotype‐genotype heterogeneity. In this review, the usage and limitations of diagnostic methods for membranopathies in Asian countries were evaluated. A systematic review was done using articles from PubMed, Google Scholar, and EBSCO from 2000 to 2020. Thirty‐six studies conducted in seven Asian countries had used different diagnostic methods to confirm membranopathies. In 58.3% of studies, full blood count (FBC), reticulocyte count, and peripheral blood smear (PBS) were used in preliminary diagnosis. The combination of the above three with osmotic fragility (OF) test was used in 38.8%. The flowcytometric osmotic fragility (FC‐OF) test was used in 27.7% where it showed high sensitivity (92%–100%) and specificity (96%–98%). The eosin‐5‐maleimide (EMA) assay was used in 68.1% with high sensitivity (95%–100%) and specificity (93%–99.6%). About 36.1% of studies had used sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE) as a further diagnostic method to detect defective proteins. Genetic analysis to identify mutations was done using Sanger sequencing, next‐generation sequencing (NGS), and whole‐exome sequencing (WES) in 33.3%, 22.2%, and 13.8% of studies, respectively. The diagnostic yield of NGS ranged from 63% to 100%. Proteomics was used in 5.5% of studies to support the diagnosis of membranopathies. A single method could not diagnose all membranopathies. Next‐generation sequencing, Sanger sequencing, and proteomics will supplement the well‐established screening and confirmatory methods, but not replace them in hereditary hemolytic anemia assessment.